3-硝基-4-丙基氨基苯甲酸 | 68740-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-硝基-4-丙基氨基苯甲酸
• 英文名称: 3-nitro-N⁴-propylaminobenzoic acid
• 英文别名: 3-nitro-4-propylaminobenzoic acid；4-propylamino-3-nitrobenzoic acid；3-nitro-4-(propylamino)benzoic acid；3-nitro-4-n-propylaminobenzoic acid；4-propylamino-3-nitro-benzoic acid
• CAS: 68740-31-8
• 化学式: C₁₀H₁₂N₂O₄
• mdl: MFCD02089273
• 分子量: 224.216
• InChiKey: OVDGUTHABMXVMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-硝基-4-丙基氨基苯甲酸 在 镍 溶剂黄146 作用下， 以 甲醇 为溶剂， 生成 3-氨基-4-丙基氨基苯甲酸
  参考文献：
  名称：

  5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives

  摘要：

  具有抗过敏和抗组胺作用的新型5-[4-(二芳基甲基)-1-哌嗪基烷基]苯并咪唑衍生物。

  公开号：

  US04179505A1
• 作为产物：
  描述：

  正丙胺 、 4-氯-3-硝基苯甲酸 反应 5.0h， 生成 3-硝基-4-丙基氨基苯甲酸
  参考文献：
  名称：

  Synthesis and biological evaluation of novel dabigatran derivatives as thrombin inhibitors

  摘要：

  合成了一系列新型 3-[{2-[(4-氨基甲酰基苯基氨基)甲基]-1-取代-1H-苯并咪唑-5-甲酰基}(3-氯-4-氟苯基)氨基]丙酸达比加群衍生物。化合物的结构通过 1H NMR、13C NMR、HRMS 和元素分析进行了表征。对化合物进行了体外凝血酶抑制活性筛选。结果表明，这些化合物具有低度到中度的抑制活性。具有 N-甲基和 N-乙基侧链的化合物对凝血酶的抑制活性远高于具有其他侧链的化合物。

  DOI：

  10.1007/s11164-015-2053-y

文献信息

• [EN] BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF<br/>[FR] BENZOTRIAZOLES ET PROCEDES DE PREVENTION OU DE TRAITEMENT DES TROUBLES METABOLIQUE
  申请人：ARENA PHARM INC

  公开号：WO2004041274A1

  公开（公告）日：2004-05-21

  The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR referred to as hRUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

  本发明涉及公式（I）的若干苯并三唑羧酸或酯衍生物，其药学上可接受的盐和溶剂化物，具有有用的药理特性，例如作为称为hRUP38的GPCR激动剂。本发明还提供了含有本发明化合物的药物组合物，以及使用本发明化合物和组合物在预防或治疗代谢相关疾病，包括血脂异常、动脉粥样硬化、冠心病、胰岛素抵抗、2型糖尿病、综合征X等方面的方法。此外，本发明还提供了将本发明化合物与属于-葡萄糖苷酶抑制剂、醛还原酶抑制剂、双胍类、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、非酯类、LDL降解增强剂、血管紧张素转化酶（ACE）抑制剂、胰岛素分泌增强剂等类别的其他活性剂联合使用的方法。
• Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
  申请人：Semple Graeme

  公开号：US20060122240A1

  公开（公告）日：2006-06-08

  The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR referred to as hRUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

  本发明涉及公式（I）的某些苯并三唑羧酸或酯衍生物，其药学上可接受的盐和溶剂，具有有用的药理特性，例如作为被称为hRUP38的GPCR的激动剂。本发明还提供了含有该发明化合物的制药组合物，以及使用该发明化合物和组合物在预防或治疗代谢相关疾病，包括脂质代谢异常、动脉粥样硬化、冠心病、胰岛素抵抗、2型糖尿病、综合征X等方面的方法。此外，本发明还提供了将该发明化合物与属于-葡萄糖苷酶抑制剂、醛糖还原酶抑制剂、双胍类药物、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、纤维酸类、低密度脂蛋白降解增强剂、血管紧张素转换酶（ACE）抑制剂、胰岛素分泌增强剂等类别的其他活性剂一起使用的方法。
• Agent for treatment or prevention of diseases associated with activity of neurotrophic factors
  申请人：Ishikawa Junichi

  公开号：US08829035B2

  公开（公告）日：2014-09-09

  A compound depicted by the formula below, or a pharmaceutically acceptable salt or solvate thereof. wherein, R1 represents (1) a C3-6 alkyl group, (2) a C1-6 alkyl group substituted with one or more substituent group(s) selected from those consisting a halogen atom, etc., (3) a C3-10 non-aromatic cyclic hydrocarbon group or a 5- to 6-membered non-aromatic heterocyclic group which respectively is optionally substituted with one or more substituent group(s) selected from those consisting an oxo group, etc., (4) an aromatic cyclic hydrocarbon group substituted with one or more substituent selected from the group consisting halogen atom and C1-4 alkoxy group; X represents NH, O, or S; Y represents CH or N; Z represents N or a C—R2; R2 represents (1) hydrogen atom, (2) a C1-6 alkyl group, a C2-6 alkenyl group or a C2-6 alkynyl group that respectively is optionally substituted with one or more substituent group(s) selected from among those consisting (a) a halogen atom, etc., or (3) a C5-6 non-aromatic cyclic hydrocarbon group or a 5- to 6-membered non-aromatic heterocyclic group optionally substituted; ring A represents a benzene ring optionally substituted; ring B represents a benzene ring optionally substituted.

  以下化合物的化学式，或其药学上可接受的盐或溶剂酸盐。其中，R1代表(1) C3-6烷基，(2) C1-6烷基，其上取代有一个或多个取代基，所选取代基包括卤素原子等，(3) C3-10非芳香环烃基或5-至6-成员非芳香杂环基，分别可以选用一个或多个取代基，所选取代基包括氧代基等，(4) 芳香环烃基，其上取代有一个或多个取代基，所选取代基包括卤素原子和C1-4烷氧基；X代表NH、O或S；Y代表CH或N；Z代表N或C—R2；R2代表(1) 氢原子，(2) C1-6烷基、C2-6烯基或C2-6炔基，分别可以选用一个或多个取代基，所选取代基包括卤素原子等，或(3) C5-6非芳香环烃基或5-至6-成员非芳香杂环基，可选用取代基；环A代表一个苯环，可选用取代基；环B代表一个苯环，可选用取代基。
• AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP2436683B1

  公开（公告）日：2014-05-14
• 1-Alkyl-benzotriazole-5-carboxylic Acids Are Highly Selective Agonists of the Human Orphan G-Protein-Coupled Receptor GPR109b
  作者：Graeme Semple、Philip J. Skinner、Martin C. Cherrier、Peter J. Webb、Carleton R. Sage、Susan Y. Tamura、Ruoping Chen、Jeremy G. Richman、Daniel T. Connolly

  DOI：10.1021/jm051099t

  日期：2006.2.1

  I-Substituted benzotriazole carboxylic acids have been identified as the first reported examples of selective small-molecule agonists of the human orphan G-protein-coupled receptor GPR109b (HM74), a low-affinity receptor for the HDL-raising drug niacin. No activity was observed at the highly homologous high-affinity macin receptor GPR109a (HM74A). The high degree of selectivity was attributed to a difference in the amino acid sequence adjacent to a key arginine-ligand interaction allowing somewhat larger ligands to be tolerated by GPR109b.